GlassScriptPhysician profile
Richard E Walton
NPI 1215150271
$7,810.82
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,670 · 2022: $4,302 · 2023: $1,402 · 2024: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,839.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $2,625.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $1,354.04 | 2021-2024 | Xarelto |
| Esperion Therapeutics, INC. | $897.48 | 2021-2023 | Nexletol |
| Amgen INC. | $817.95 | 2021-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $783.80 | 2021-2024 | Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $398.27 | 2022-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $151.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.21 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $122.75 | 2021-2024 | |
| Amarin Pharma, INC. | $102.78 | 2021-2022 | |
| Pfizer INC. | $99.16 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $89.72 | 2022 | |
| Boston Scientific Corporation | $69.81 | 2021-2023 | Watchman |
| Azurity Pharmaceuticals, INC. | $38.30 | 2023 | Edarbi |
| Arbor Pharmaceuticals, INC. | $32.50 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $25.84 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $25.45 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $17.22 | 2023 | Opsumit |
| Kowa Pharmaceuticals America, INC. | $16.24 | 2021 | |
| Cvrx, INC. | $10.61 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Walton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.